Impact of Baricitinib on Patients’ Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry

The efficacy and safety of baricitinib for treatment of atopic dermatitis have been demonstrated in clinical trials; however, very few real-life studies have been published to date. The Observatory of Chronic Inflammatory Skin Diseases (OMCCI) registry was initiated to prospectively determine the long-term impairment caused by chronic inflammatory dermatoses on patients’ lives. The study included 88 patients starting baricitinib for treatment of atopic dermatitis. Clinical evaluation and patient-reported outcomes were recorded at baseline and after 6 and 12 months. After 6 months and 1 year of follow-up, 65 and 47 patients, respectively, were still being treated with baricitinib. Treatment failure was the main reason for discontinuation. Only 1 patient stopped baricitinib because of a side-effect. After 1 year of follow-up, the mean Eczema Area and Severity Index score decreased significantly from 20.7 to 6.4; the percentage of patients with severe atopic dermatitis decreased from 42.9% to 6.5% and a significant improvement in most patient-reported outcomes was noted. There was no difference in terms of efficacy whether or not patients were previously treated with dupilumab. The results remained stable after 6 and 12 months of treatment, which suggests a sustained efficacy of the treatment in patients who initially responded well

Les biothérapies : enquête de pratique auprès des dermatologues et rhumatologues du bassin sanitaire du CHU de Reims

REIMS-BU Santé (514542104) / SudocSudocFranceF

Efficacité et tolérance au long cours de l'infliximab dans le traitement de l'hidradénite suppurée modérée à sévère

REIMS-BU Santé (514542104) / SudocSudocFranceF

Intérêt de l'E.L.I.S.A pour le diagnostic et le suivi des dermatoses bulleuses auto-immunes

REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Evaluation de l'efficacité des bolus de méthylprednisolone dans le traitement des pelades étendues

REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Syphilis : changement épidémiologique au CHU de Reims : 1993-2007

REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Traitement des cicatrices chéloïdes par injections intra-lésionnelles de bléomycine (suivi au long cours)

REIMS-BU Santé (514542104) / SudocSudocFranceF

Traitement du psoriasis par biothérapies (enquête de pratique en dermatologie et en rhumatologie au CHU de Reims)

REIMS-BU Santé (514542104) / SudocSudocFranceF

Intérêt des tests cutanés dans la prise en charge des toxidermies immuno-allergiques (l'expérience rémoise)

REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF